Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to Köhne Prognostic Category and BRAF Mutation Status-Reference-Cited by-同舟云学术

Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to Köhne Prognostic Category and BRAF Mutation Status

Published:2018-03 Issue:1 Volume:17 Page:50-57.e8
ISSN:1533-0028
Container-title:Clinical Colorectal Cancer
language:en
Short-container-title:Clinical Colorectal Cancer

Author:

Siena Salvatore,Rivera Fernando,Taieb Julien,Peeters Marc,Prenen Hans,Koukakis Reija,Demonty Gaston,Köhne Claus-Henning

Publisher

Elsevier BV

Subject

Gastroenterology,Oncology

Reference34 articles.

1. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer;Van Cutsem;Ann Oncol,2016

2. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients;Köhne;Ann Oncol,2002

3. A final analysis from the CHOICE study examining darbepoetin alfa use for chemotherapy-induced anaemia in current European clinical practice;Van Belle;Curr Med Res Opin,2012

4. Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus > or = 10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial;Vansteenkiste;BMC Cancer,2009

5. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer;Di Nicolantonio;J Clin Oncol,2008

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. First line therapy in stage IV BRAF mutated colorectal cancer;Heliyon;2024-09

2. Relationships Between Köhne Category/Baseline Tumor Load and Early Tumor Shrinkage, Depth of Response, and Outcomes in Metastatic Colorectal Cancer;Clinical Colorectal Cancer;2021-12

3. Muscle Loss Is Associated with Overall Survival in Patients with Metastatic Colorectal Cancer Independent of Tumor Mutational Status and Weight Loss;The Oncologist;2021-05-06

4. Effect of antiangiogenic-based treatment and systemic inflammatory factors on outcomes in patients with BRAF v600-mutated metastatic colorectal cancer: a real-world study in Spain;BMC Cancer;2021-01-14

5. Colorectal liver metastases: Current management and future perspectives;World Journal of Clinical Oncology;2020-10-24